
Aditxt, Inc. — Investor Relations & Filings
Aditxt, Inc. is an innovation company focused on acquiring, developing, and deploying promising health technologies. Its business model involves acquiring disruptive and scalable companies, leveraging its business acceleration platform to drive growth, and monetizing assets through various strategies including mergers, sales, and licenses. The company's portfolio of programs targets significant health challenges. Current programs include Adimune, focused on autoimmunity; Pearsanta, for early cancer detection; and Adivue, for neurological diagnostics. Aditxt also has planned programs and proposed acquisitions in areas such as reproductive health.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | |
| S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | |
| 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | |
| DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 34484140 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | ||
| 34402623 | S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | ||
| 33743863 | 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | ||
| 33302978 | DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | ||
| 33158825 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | ||
| 33087919 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English | ||
| 33066090 | 424B5 - Aditxt, Inc. (0001726711) (Filer) | 2026-03-27 | English | ||
| 31498298 | 8-K Filing | 2026-02-13 | English | ||
| 31498392 | 8-K Filing | 2026-01-30 | English | ||
| 31498344 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31498281 | 8-K Filing | 2026-01-28 | English | ||
|
2025
4 filings
| |||||
| 13087095 | Director's Dealing 2025 | 2025-12-19 | English | ||
| 13087096 | DEFINITIVE PROXY STATEMENT | 2025-12-16 | English | ||
| 13087097 | PROSPECTUS SUPPLEMENT | 2025-12-12 | English | ||
| 13087099 | REVISED PRELIMINARY PROXY STATEMENT | 2025-12-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
VALIRX PLC
Life science company developing therapeutics for oncology a…
|
VAL | GB | Professional, scientific and te… |
|
Vanta Bioscience Limited
A contract research organization providing preclinical safe…
|
540729 | IN | Professional, scientific and te… |
|
Vaxil Bio Ltd.
Uses a proprietary Signal Peptide platform to develop immun…
|
VXL | CA | Professional, scientific and te… |
|
Vcanbio Cell & Gene Engineering Corp., Ltd
Focuses on stem cell bio-banking, genetic testing, and cell…
|
600645 | CN | Professional, scientific and te… |
|
VECTUS BIOSYSTEMS LIMITED
Develops therapeutics to reverse fibrosis and hypertension …
|
VBS | AU | Professional, scientific and te… |
|
Veradermics, Inc
Clinical-stage biopharmaceutical company developing medical…
|
MANE | US | Professional, scientific and te… |
|
Vera Therapeutics, Inc.
Clinical-stage biotech developing treatments for immunologi…
|
VERA | US | Professional, scientific and te… |
|
Veritas In Silico Inc.
A drug discovery company developing mRNA-targeting therapeu…
|
130A | JP | Professional, scientific and te… |
|
ViGenCell Inc.
Develops immune cell therapies to treat cancer and other in…
|
308080 | KR | Professional, scientific and te… |
|
Viking Therapeutics, Inc.
Clinical-stage biopharma developing therapies for metabolic…
|
VKTX | US | Professional, scientific and te… |
Aditxt, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35447/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35447 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35447 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35447 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35447}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aditxt, Inc. (id: 35447)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.